Subject Index

A1 receptor, pathways of signal transduction and, 44
Adaptation, adaptive systemic structural trace and selective gene expression and, 371
Adenosine
  antiadrenergic effect of, 64
  endogenous, 65
  ischemic preconditioning and, 346
  late preconditioning and, 165
Adenosine deaminase, tissue adenosine and, 66
Adenosine receptor antagonists, protection of ischemic preconditioning blocked by, 177
Adenosine receptors
  noradrenaline and, 50
  ventricular myocardium and, 64
Adenosine triphosphate (ATP), global ischemia and, 310
[^{35}S]-Adenosine-5′-(γ-thio)triphosphate, sarcolemmal membranes and, 2
α1-Adrenergic receptor, pathways of signal transduction and, 44
Adrenergic stimulation, 18
Age
  antioxidant enzymes and, 439
  heat-shock-mediated cardioprotection and, 173
  lipid peroxidation and, 449
  redox potential and, 299
  type of cell and, 359
Aging, myocardium and, 305
α-Amanitin, transcription-dependent DNA excision-repair and, 315
Amiloride, sodium-calcium exchange and, 151
Anchored primers, 244
Angiotensin II (Ang II) receptors, myocardial, 466
Anoxia, glycogen stores and, 78
Anti-PLD antibodies, 485
Antioxidant
  fetal cells exposed to hyperoxia and, 505
  glutathione as, 404
Antioxidant concentration, redox potential and, 299
Antioxidant enzymes, postnatal developmental profiles of, 439
Aortic valve replacement, 437
Aprotinin
  endothelial cell damage and, 514
  oxidative stress and, 521
Arbitrary primers, 244
Arrhythmias, cromakalim and glibenclamide and, 460
Ascorbate oxidase gene expression, putative, 293
Aspartate, cardiac surgery and, 348
ATP-binding assay, sarcolemmal membranes and, 2
Attachment time, cross-bridge, 60

BBF-1, cardiac-specific transcription factor, 262
Beta-oxidation pathway, 444

Calcium, senescent myocardium and, 307
Calcium channel antagonists, newer, 349
Calcium paradox, hamster heart resistant to, 456
Calcium transient, stunned myocardium and, 150
Calcium-uptake and binding by cardiac sarcoplasmic reticulum, 400
Calnexin, stress and, 479
Capillary endothelium, adaptive reorganization of, 423
Captopril
  mineral and vitamin levels and, 519
  myocardial Ang II receptors and, 468
Carbonyl compounds, 433
Cardiac muscle differentiation, 261
Cardiac pacing, antiarrhythmic effect of, 101
Cardiocyte cell specification, molecular basis of, 259
Cardiogenesis, early marker for, 262
Cardiogenic shock, monophosphoryl lipid A (MLA) and, 391
Cardiomyocytes
  phospholipase D and, 217
  TNF-α-induced cytoprotective mechanisms in, 267
Cardiomyopathy, atrial natriuretic factor (ANF) and, 421
Cardioplegia
  insulin-enhanced, 497
  intermittent antegrade, 329
  intermittent doses of, 339
  potassium, 308
  retrograde, 340
  tepid, 434
  warm versus cold blood, 329

Cardioplegic arrest, CoQ_{10} and, 415
Cardioplegic solutions, comparative study of, 360
Cardioprotection
  brief mesenteric artery occlusion and, 33
  brief renal artery occlusion and, 33
  endogenous adenosine and, 71
  monophosphoryl lipid A (MLA) and, 387
  natriuretic factor (ANF) and, 421
  ventricular pacing and, 37
Cardiopulmonary bypass, glutathione and, 400
Carmeda circuit, 511
Catalase (CAT)
  age-related alterations in, 449
  HSP 72 and, 168
  rabbit heart and, 441
Catecholamines
  β-adrenergic, 65
  Mg^{2+} fluxes and, 474
  preconditioning simulated by, 44
Cation content, myocardial, 149
CD marker expression abnormalities, Kuwaiti population and, 501
cDNA, reamplified, 243
Cell maturity, classification of, 357
Cell signaling, ischemic preconditioning and, 43
Cell typing, criteria for, 357
CGS-15943, adenosine A_2 receptor activation and, 69
Chemiluminescence, 508
Chemiluminescent activity of PMNLs (PMNL-CL), 402
Chlorostyryl-caffeine, 69
Cibacron blue, ATP-binding and, 4
Code for inducing cardioadaptation, 227
Coenzyme Q_{10} (CoQ_{10}), myocardial tolerance to ischemia/reperfusion injury and, 414
Continuous capillary perfusion, 331
Contractile recovery, endogenous adenosine and, 71
Contractility
  DPCPX and PIA and, 68
  myocardial, 320
Contractility of cardiomyocytes, TNF-α and, 271
Coronary artery bypass surgery (CABG), risks of, 338
Coronary revascularization
  myocardial temperature and, 319
  normothermic ischemia in, 328
Coronary sinus, retrograde flow and, 341
Creatine kinase, post-pump myocardial dysfunction and, 402
Cromakalim, 460
Cross-bridge cycle, V_1 and V_3 myosin heavy chain and, 54
Crosstolerance, ischemic induction of HSP 70i and, 124
Cycling rate, cross-bridge, 59
Cytochrome oxidase, impaired mitochondrial function and, 311
Cytoprotective mechanisms, TNF-α-induced, 267

Delayed cardioprotection, endothelium-derived mediators involved in, 104
Developmental status, myocardial protection and, 355
Diabetes, myocardial Ang II receptor characterization in, 468
Diacylglycerol, phospholipase D and, 200
1,2-Diacylglycerol, PKC isoforms and, 211
DIDS (4,4′-diisothiocyanatostilbene), ATP-binding and, 3
Diet, Mg^{2+}, 475
Differential display techniques, 241
Differential gene expression, 249
1,3-Dipropyl-8-cyclopentylxanthine (DPCPX), 65
DNA, 8-OHDG and, 427
DNA fragmentation, mature and aged, 313
DNA molecules, oxygen free radicals and, 433
DNA strand breaks, 433
Dog, adenosine receptor blockade in, 85

Electromechanical arrest, warm heart surgery and, 332
Electron spin resonance (ESR), myocardial NO content assessed by, 490
End-diastolic pressure-volume relationship (β) (EDPVR), 323
End-systolic pressure-volume relationship (ESPVR), 323
Endogenous antioxidant activity, oxygen-derived radicals and, 164
Endogenous antioxidants, hypertrophied heart and, 152
Endothelium, cardiac myocytes and, 100
Endotoxic shock, 506
Endotoxin, no immediate protection by, 104
Energy metabolism, downregulation of, 92
Environmental toxins, 498
Enzymatic antioxidants, patterns of, 368
Extracellular calcium, heat-shocked heart and, 172

Ferritin, iron release and, 81
Fetal type II pneumocytes, 505
Forskolin, Mg^{2+} fluxes and, 474
Free radicals
  anoxia and, 164
  CoQ_{10} and, 416
  heat shock proteins and, 110
Functional preconditioning, correlation of stimulated PKC isoform profiles with, 236

G-6-P dehydrogenase, rabbit heart and, 443
GABAergic system, stress and, 378
Gel electrophoresis, cDNA fragments and, 250
Gene expression
  adaptation and, 371
  HSP 70, 109
  rationale for, 240
Genistein, phospholipase D and, 196
Glibenclamide, 460
Global ischemia, isolated retrogradely perfused heart and, 125
Glucagon, 80
Glucose
  insulin and, 494
  interruption of, 186
Glucose and insulin, cardiac surgery and, 348
Glutamate, cardiac surgery and, 348
Glutathione (GSH)
  age-related changes in, 449
  myocardial dysfunction and, 400
Glutathione cycle, 446
Glutathione peroxidase, rabbit heart and, 441
Glutathione reductase, rabbit heart and, 440
Glycogen, depletion of, 76
Glycogenolysis, reduced, 93
Gulf War in 1991, 498

H_2O_2, specific ATP-binding and, 5
Heart
  gene expression in, 254
  hamster, 456
  Mg^{2+} in, 473
  newborn, 447
  rabbit, 439
Heart function, PLD activity and, 486
Heat shock protein (HSP), free radicals and, 110
Heat shock protein 27 (HSP 27), TNF-α and, 275
Heat shock protein 70 (HSP 70)
  accumulation of, 381
  calnexin and, 479
  TNF-α and, 275
  windows for, 167
Heat shock protein 72 (HSP 72), postischemic improvement and, 167
Heat stress preconditioning, redox potential and, 300
Heparin-coated tubing, 511
High-performance liquid chromatography (HPLC), CoQ_{10} and, 416
HOCl, specific ATP-binding and, 6
8-Hydroxydeoxyguanosine (8-OHDG), 427
Hydroxyl radical (OH·)
  deoxyguanosine and, 427
  NADPH and, 445
Hyperoxia, neonatal animals and, 504
Hypothermic coronary artery bypass graft (CABG), glucose and insulin in, 494

Infarct size
  body temperature and, 28
  in situ heart and, 127
  monophosphoryl lipid A (MLA) and, 387
  transmural distribution of, 28
Inositolphosphates, PKC-mediated preconditioning and, 218
Inotropic agents, stunned myocardium and, 151
Inotropic response, isoproterenol-elicited, 70
Insulin
  glucose and, 494
  myocardial Ang II receptors and, 468
Intracellular pH, glycogen depletion and, 79
Intracellular signal transduction, Takayasu's arteritis and, 453
Iron, 520
Iron release, 75
Ischemia
  adenosine A_1 receptor stimulation and, 67
  atrial natriuretic factor (ANF) and, 419
  elderly patients and, 306
Ischemia/reperfusion
  hypertrophied heart and, 146
  myocardial gene expression and, 201
Ischemia/reperfusion injury, oxidative damage to myocardial proteins and DNA during, 431
Ischemic injury, lethal, 14

Ischemic metabolism, facets of, 13
Ischemic myocardium, capillary endothelium in, 423
Ischemic preconditioning
  adenosine agonists and, 178
  antiarrhythmic effect of, 101
  cell signaling in, 48
  classical, 99, 102
    heat stress proteins and, 129
  clinical implications for, 22
  coronary artery bypass surgery and, 338
  free radicals and, 110
  high-energy phosphate utilization and, 16
  history and definition of, 14
  HSP 70 and, 110
  late, 156
  mechanism of, in myocardium, 210
  metabolic effects and, 15, 85
  molecular signaling and, 191
  monophosphoryl lipid A (MLA) and, 386
  nitric oxide in, 489
  oxygen-derived free radicals and, 156
  PCR-DDR technique and, 252
  phospholipase D and, 485
  protein kinase C in, 177
  reduced glycolytic rate and, 16
  translocation theory of, 181
Ischemic reperfused myocardium, 8-OHDG in, 427
Ischemic reperfusion injury, CoQ_{10} and, 416
Isoproterenol (ISO), DPCPX and, 66

K_{ATP}^{+} (ATP-dependent K^+), ventricular pacing and, 37
K_{ATP}^{+} (ATP-dependent K^+) channels, inhibition of, 20
Kuwaiti population, abnormal lymphocyte surface antigen expression in, 498

Lactate
  atrial natriuretic factor (ANF) and, 421
  tepid cardioplegia and, 497
Left ventricular afterload, heat-shock procedure and, 170
Lipid peroxidation (LP)
  age-related alterations in, 449
  CoQ_{10} and, 414
Load, systemic structural trace of adaptation and, 372
Low molecular weight iron, 74
Lung disease, 504
Lymphocyte surface antigen, Kuwaiti population and, 498

Magnesium homeostasis, diet and, 473
Malonaldehyde, CoQ_{10} and, 415
Malondialdehyde (MDA)
  endotoxin and, 506
  post-pump cardiac dysfunction and, 400
MAP kinase, 192
MAPKAP kinase 2, 192
MB isoenzyme of creatine kinase (MBCK), 400
Mechanical cardiorespiratory support (CMCS), 521
Mechanisms of cardiac protection, 135
MEF-2 family of transcription factors, 261
Microdialysis, dog cardiac, 86
Mineral and vitamin levels, 519
Mitochondrial ATPase
  decline in ATP during ischemia and, 18
  inhibition of, 19
Mitochondrial DNA, deletion from, 284–285
Monophosphoryl lipid A (MLA), characterization of, 387
mRNA
  HSP 70, 113
  L23a, 256
mRNA phenotyping, cytoprotective mechanisms in cardiomyocytes and, 267
mRNA species, PCR-DDR approach and, 256
Myocardial dysfunction, glutathione and, 400
Myocardial hypertrophy, HSP 72 and, 171
Myocardial infarction, mitochondrial DNA deletion and, 284
Myocardial protection
  coronary bypass surgery and, 350
  pediatric, 355
Myocardial stunning
  monophosphoryl lipid A (MLA), and, 396
  preconditioning and, 19
Myocardium, LADCA-perfused, 214
Myocytes, anoxia and, 157
Myosin heavy chain (MHC), V_1 versus V_3, 54
Myosin isozymes, 283
Myothermal measurements, papillary muscle and, 55

Na/K ATPase, norepinephrine and, 44
Neonatal animals, hyperoxia in, 504
Nitric oxide, preconditioning and, 489
Nonenzymatic antioxidants, patterns of, 368
Norepinephrine, arrhythmias and, 44

Normothermic blood cardioplegia, postoperative low output syndrome and, 342
Normothermic coronary artery bypass graft (CABG), glucose and insulin in, 494
Normothermic ischemia, coronary revascularization and, 328
Northern hybridization, genes and, 255
Nuclei, adaptation and, 380

$\cdot O_2^-$, measurement of, 158
Open heart surgery, reactive oxygen species and, 366
Oxidative stress
  aprotinin effects related to, 521
  CoQ_{10} and, 416
  endotoxemia and, 506
Oxygen free radicals
  DNA molecules and, 433
  pattern of, 368
  post-pump cardiac dysfunction and, 400
Oxygen-derived free radicals, active, 156

P2-purinoceptors, high-affinity ATP-binding and, 8
Papillary muscles, V_1 versus V_3 myosin heavy chain and, 54
Partial coronary occlusion, preconditioning by, 28
Pediatric myocardial protection, 355
Phenomenon of adaptive stabilization of structures (PhASS), 377
Phenylisopropyl-adenosine (PIA), reperfusion and, 68
Phorbol myristate acetate (PMA), PKC activated by, 211
Phosphatydlalcohol, phospholipase D pathway and, 219
Phospholipase C-β, activation of, 211
Phospholipase D (PLD)
  activation of, 211
  diacylglycerol levels and, 485
  estimation of, 193
  PKC hypothesis of preconditioning and, 186
Phospholipase D (PLD) signaling pathway, 487
Phosphorylation, protein, 314
Physiological studies, Mg^{2+} efflux and, 474
Pig, ischemic preconditioning in, 45
Polymerase chain reaction products, 246
Polymerase chain reaction-based differential display techniques (PCR-DDR), advantages of, 241
Polymerase chain reaction-TRAP cloning, 246
Polymorphonuclear leukocytes (PMNL), post-pump cardiac dysfunction and, 400
Potassium channel, ATP-sensitive, 386
Preconditioning/adaptation, intracellular signaling and, 206
Preconditioning/cardioadaptation, PKC in, 235
Propranolol, mineral and vitamin levels and, 519
Protein denaturation, stress-induced increase in HSP 70 and, 118
Protein kinase C (PKC)
  classical ischemic preconditioning and, 134
  diacyglycerol (DAG) and, 21
  high-energy phosphate and, 18
  ischemic preconditioning and, 177
  mechanism of ischemic preconditioning in myocardium and, 210
  second window of protection and, 134
  signal transduction mechanisms and, 44
  translocation of, 213
Protein kinase C activation, 179
Protein kinase C inhibitors, infarct size and, 212
Protein kinase C isoforms
  distribution of, 230
  similarities and dissimilarities of, 233
  stimulated translocation of, 231
Protein kinase C-linked stimuli, protection of functional recovery by, 231
Protein kinase C-ε, translocation of, 213
Protein tyrosine kinase, phospholipase D and, 192
Pyruvate dehydrogenase (PDH), 347

Rat, arrhythmias in, 44
Rat ribosomal protein L23a, 248
Reactive oxygen species, open heart surgery and, 366
Red wine, plasma redox potential and, 299
Redox potential
  aprotinin and, 514
  equation for, 290
Redox state, hypertrophied heart and, 152
Regional ischemia, isolated retrogradely perfused heart and, 125
Reperfusion
  intervening, necessity of, 28
  isoproterenol-free, 67
  second window of preconditioning and, 386

Retrograde cardioplegia, coronary bypass surgery and, 340
RNA, total cellular, 242
RNA blot analysis, cDNA bands reproduced on, 253

Sarcomeric gene expression, regulation of, 259
Second messengers, preconditioned-mediated, 206
Second window of protection
  clinical implications of, 134
  ischemia-induced arrhythmias and, 103
  signaling in, 133
  studies related to, 132
  sublethal ischemia and, 131
Sequencing gel, mRNA species and, 252
Severe isolated aortic stenosis, 437
Signal transduction, mRNA accumulation and, 204
Simulated ischemia, *in vitro* models of, 126
Sodium-calcium exchange
  inotropic action of low Na^+ perfusion and, 151
  stunned heart and, 148
Stimuli, similarities and dissimilarities between, 234
Stress, calnexin and, 479
Stress proteins, oxidative stress and, 165
Stress-limiting systems, adaptation and, 377
Structural trace, adaptive systemic, 371
Structure of cardiomyocytes, TNF-α and, 271
Stunning
  hypertrophied heart and, 146
  myocardial, 319
Subtractive hybridization, upregulated genes and, 255
Sucrose, Mg^{2+} fluxes and, 474
Superoxide dismutase (SOD)
  age-related alterations in, 449
  rabbit heart and, 440
Superoxide dismutase (SOD) activity, measurement of, 158
Suramin, ATP-binding and, 3

T cells, Takayasu's arteritis and, 453
Takayasu's arteritis, 453
Temperature, myocardial, 319
Tension dependent heart (TDH), cross-bridge parameters and, 57
Tepid cardioplegia, lactate and acid washout and, 343
Theophylline, metabolism of preconditioned tissue and, 90
Transgenic studies, HSP 70i, 136
Transgenic-overexpressing GSHPx-1 mice, 193, 200
Translocation theory of ischemic preconditioning, 181
Tumor necrosis factor α, cytoprotective mechanisms and, 267

Ubiquitin, TNF-α and, 278
Ultrastructural analysis, adaptive reorganization of capillary endothelium and, 423
Unitary force, cross-bridge, 60
Upregulated genes, subtractive hybridization and, 255

Ventricular arrhythmias, cardiac pacing and, 98
Ventricular fibrillation (VF), PLD activity and, 486
Ventricular pacing, cardioprotection and, 37
Ventricular tachycardia (VT), PLD activity and, 486
Vitamin E, cardiac surgery and, 349

Warm heart surgery, chemical electromechanical arrest and, 330–331
Whole body heat stress, heart and, 124

Xanthine oxidase, developed pressure and, 111

Index of Contributors

Abel, J. G., 328–337
Al-Harbi, S. A., 498–503
Alpert, N. R., 54–63
Ashraf, M., 156–166
Aslam, M., 517–520

Bagchi, D., 414–418, 427–430, 449–452
Bagchi, M., 449–452
Baig, M. A., 419–422
Baker, J. E., 439–448
Balogh, N., 489–493
Banerjee, A., 226–239
Barančík, M., 43–53
Bezstarosti, K., 210–225
Bhandari, V., 504–505
Bharadwaj, B., 400–413
Bocchieri, K. A., 511–513, 514–516
Broche, V. F., 521–524
Burleson, J. A., 498–503
Butler, K., 226–239

Carson, S. M., 494–497
Céspedes, E. M., 521–524
Chan, W. P., 400–413
Chen, G., 289–304
Christakis, G. T., 494–497
Cleveland, J., 226–239
Cohen, G., 338–354, 494–497
Cohen, J. R., 289–304
Cohen, M. V., 177–190
Cordis, G. A., 427–430, 431–436, 485–488
Cornelussen, R., 167–176
Csonka, C., 489–493
Csont, T., 489–493

Das, D. K., xi, 191–209, 240–258, 414–418, 427–430, 431–436, 439–448, 460–465, 485–488
Dash, S. K., 414–418
Deaton, D. W., 319–327
Dekkers, D. H. W., 210–225
Dhalla, A. K., 142–155
Dhalla, N. S., 1–12
Dhawan, V., 366–370
Dobson, J. G., Jr., 64–73
Downey, J. M., 177–190
Duncker, D. J., 27–42
Dux, L., 489–493

Eghbali, K. D., 419–422
Elliott, G. T., 386–399
Engelman, D. T., 319–327
Engelman, R. M., 191–209, 240–258, 319–327, 414–418, 439–448, 460–465
Eskildsen-Helmond, Y. E. G., 210–225

Fenton, R. A., 64–73
Ferdinandy, P., 489–493
Fernàndez, G. E., 521–524
Flack, J. E., III, 319–327
Florilli, R., 437–438
Fremes, S. E., 328–337

Gamboni-Robertson, F., 226–239
Ganguly, N. K., 366–370, 453–455
Garcia, J. C., 521–524
Gho, B. C. G., 27–42, 210–225
Goswami, S. K., 259–266
Goto, M., 177–190
Graver, L. M., 289–304, 511–513, 514–516
Gregory, C. A., 319–327
Gupta, A., 366–370
Gupta, R., 366–370

Haines, D. D., 498–503
Harlow, G. L., 511–513, 514–516
Hayashi, Y., 282–288
Hess, M. L., 108–122
Hirai, H., 355–365
Hoeschen, R. J., 466–472
Howarth, F. C., 473–478
Hustler, B. I., 473–478

Ikonomidis, J. S., 338–354, 494–497
Ishikawa, T., 355–365
Ivanov, J., 494–497
Iwai, T., 282–288

Jain, S., 453–455

Kalra, J., 400–413
Karas'kov, A. M., 423–426
Kaszala, K., 98–107
Kazanskaya, G. M., 423–426
Khaper, N., 142–155
Khatter, J. C., 466–472
Koltai, M., the late, 489–493
Koning, M. M. G., 27–42
Kontos, M. C., 108–122
Korchazhkina, O. V., 85–97
Koster, J. F., 74–84
Kral, J. G., 419–422
Kresch, M., 504–505

Kreutzer, D. L., 498–503
Kukreja, R. C., 108–122

Lamers, J. M. J., 210–225
Levitsky, S., 305–318
Lichtenstein, S. V., 328–337
Löw-Friedrich, I., 267–281
Lupino, R., 437–438

Madhulika, S., 366–370
Mahmoud, F. F., 498–503
Maitra, S. C., 456–459
Malyshev, I. Yu., 371–385
Marber, M. S., 123–141
Maulik, G., 414–418, 431–436
Maulik, N., 191–209, 240–258, 439–448, 504–505
McCabe, M., 498–503
McCully, J. D., 305–318
Meerson, F. Z., 371–385
Meldrum, D. R., 226–239
Meng, X-Z., 226–239
Merante, F., 494–497
Metz, H. N., 289–304, 511–513, 514–516
Mickle, D. A. G., 494–497
Mitchell, M. B., 226–239
Musat, S., 1–12

Nakamura, I., 282–288
Nemoto, S., 282–288
Niaz, M. A., 517–520
Núñez, P., 521–524

Olembe, E., 521–524
Ota, Y., 282–288

Palazzo, R. S., 289–304, 511–513, 514–516
Pancza, D., 43–53
Papp, J. Gy., 98–107
Parratt, J. R., 98–107
Pattanaik, U., 506–510
Patterson, E. B., 449–452
Peterson, J. N., 54–63
Pisarenko, O. I., 85–97
Popescu, L. M., 485–488
Prasad, K., 400–413, 506–510
Prieto, E., 521–524
Pshennikova, M. G., 371–385
Puri, G. D., 366–370

Rajakumar, A. R. J., 479–484
Rao, P. S., 289–304, 511–513, 514–516
Rao, S. K., 289–304, 511–513, 514–516
Rao, V., 338–354, 494–497
Rastogi, S. S., 517–520
Ratna, M. S., 366–370
Ravingerová, T., 43–53
Ray, M., 456–459
Rehring, T. F., 226–239
Reimer, K. A., 13–26
Remsey, E. S., 419–422
Reneman, R. S., 167–176
Reynoso, E., 521–524
Riedel, W., 427–430
Rifkin, R. D., 319–327
Rousou, J. A., 319–327
Ruigrok, T. J. C., 74–84

Sadri, P., 466–472
Sawmiller, D. R., 64–73
Schaper, W., 43–53
Schoemaker, R. G., 27–42
Serebryakova, L. I., 85–97
Shapiro, J. I., 226–239
Sharma, B. K., 453–455
Sharma, H. S., 267–281
Sharma, K., 366–370
Shikata, C., 282–288
Shunkin, A. V., 423–426
Siddiqui, M. A. Q., 259–266, 419–422
Singal, P. K., 142–155
Singh, J., 473–478
Singh, R. B., 517–520
Slezák, J., 43–53
Sluiter, W., 74–84
Snoeckx, L. H. E. H., 167–176
Soei, L. K., 210–225
Stohs, S. J., 427–430, 449–452
Studneva, I. M., 85–97
Styk, J., 43–53
Suárez, A. R., 521–524
Suri, R. K., 366–370
Szilvássy, Z., 489–493

Takaichi, S., 355–365
Takeda, N., 282–288
Tanaka, Y., 282–288
Tanamura, A., 282–288
Tang, L., 449–452
Tesler, U. F., 437–438
Thingnam, S. K. S., 366–370
Tighe, D. A., 319–327
Tomasco, B., 437–438
Tosaki, A., 460–465, 485–488
Trifan, O. C., 485–488
Tskitishvily, O. V., 85–97

Van der Vusse, G. J., 167–176
Van Heugten, H. A. A., 210–225
Varga, M., 419–422
Vegh, A., 98–107

Verdouw, P. D., 27–42, 210–225
Vinayagamoorthy, T., 479–484
Volkov, A. M., 423–426
Voogd, A., 74–84

Wait, R. B., 419–422
Waring, J. J., 473–478
Weisel, R. D., 338–354, 494–497
Weisensee, D., 267–281
Wilson, D. W., 289–304, 511–513, 514–516

Yagihara, T., 355–365
Yamamoto, F., 355–365
Yellon, D. M., 123–141
Yoshida, T., 191–209, 414–418

Zhai, X., 156–166
Zhang, M., 466–472
Zhou, X., 156–166
Ziegelhöffer, A., 43–53
Zu, Y-L., 191–209